Please assess the completion status of the following clinical trial:

Trial Title: The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female \> 18 years of age;~* Documentation of heart failure and who are in NYHA class II or III;~* Documented history of symptomatic AF \< 6 months in duration at the time of presentation, currently in AF at the time of the external electrical cardioversion, and successfully restored to normal sinus rhythm;~* Percutaneous coronary intervention (PCI) patients who can be placed on anticoagulation with warfarin post-cardioversion (and not on rivaroxaban or dabigatran);~* Demonstration of preserved ejection fraction (EF) by echocardiography;~* Echocardiographic evidence of impaired diastolic filling.~Exclusion Criteria:~* Known history of permanent or long-standing AF (\> 6 months);~* Other acutely reversible causes of AF, including but not limited to: hyperthyroidism, pericarditis, myocarditis or pulmonary embolism;~* Known history of cirrhosis;~* NYHA Class IV;~* Myocardial Infarction, unstable angina, or coronary artery bypass graft surgery within three months prior to screening;~* Percutaneous coronary intervention (PCI) within 4 weeks prior to screening, if these patients need to be placed on rivaroxaban or dabigatran post-cardioversion;~* Clinically significant valvular disease;~* Clinically significant pulmonary disease;~* Stroke within 3 months prior to screening;~* Creatinine clearance \< 30 mL/min as calculated by Cockcroft-Gault formula;~* Use of anti-arrhythmic drugs (Class Ia or IIIc) within 3 months prior to screening;~* Concurrent use of drugs considered strong inhibitors of CYP3A;~* Concurrent use of drugs considered as CYP3A inducers;~* Prior treatment with ranolazine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).